Filtered By:
Source: Heart Rhythm
Drug: Beta-Blockers
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Blocking interleukin-6 Trans-Signaling in AF: Promises and Challenges
Atrial fibrillation (AF) stands as the most prevalent cardiovascular disease, posing significant risks of stroke, heart failure, and other complications that contribute to morbidity and mortality. While traditionally research on AF has primarily focused on electrophysiological components like ionic currents and the Ca2+ handling system, treatment strategies have mainly revolved around the rate-limiting beta-blockers and Ca2+ channel blockers, or rhythm-control methods such as cardioversion, antiarrhythmics, and catheter ablation.
Source: Heart Rhythm - September 9, 2023 Category: Cardiology Authors: Enrique Martinez, Na Li Source Type: research
